NCT02120911View on ClinicalTrials.gov

Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

February 28, 2017

Study Completion Date

February 28, 2017

Conditions
Esophageal Carcinoma
Interventions
DRUG

Pertuzumab, trastuzumab

Pertuzumab and trastuzumab will be combined with standard chemoradiation with carboplatin and paclitaxel.

Trial Locations (1)

1100 DD

Academic Medical Center, Medical Oncology, Amsterdam

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

NCT02120911 - Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma | Biotech Hunter | Biotech Hunter